OncoMatch/Clinical Trials/NCT07439497
Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer
Is NCT07439497 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies concurrent chemotherapy for cervical cancer.
Treatment: concurrent chemotherapy — This study aims to evaluate the efficacy and safety of hypofractionated intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy in patients with cervical cancer. Conventional treatment usually requires 7-8 weeks, which increases the risk of toxicities and treatment delays. This trial seeks to shorten the overall treatment time while maintaining non-inferior tumor response and survival outcomes compared to standard therapy. The primary endpoint is tumor volume reduction rate (TVRR) assessed by pelvic MRI at 1 month after treatment. Secondary endpoints include 3-year local recurrence rate, progression-free survival, and incidence of acute and late grade ≥3 toxicities. The results of this study are expected to contribute to establishing an optimal treatment strategy for cervical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIB, IIIA, IIIB, IVA (FIGO 2018)
FIGO stage IIB-IVA (2018)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pelvic radiotherapy
Patients who have previously received pelvic radiotherapy
Cannot have received: definitive chemotherapy or chemoradiotherapy
Patients who have previously received definitive chemotherapy or chemoradiotherapy for diagnosed cervical cancer
Cannot have received: surgery for current cervical cancer lesion
Patients who have undergone surgery for the current cervical cancer lesion
Cannot have received: local excisional procedures of the cervix (conization or LEEP)
Patients who underwent local excisional procedures of the cervix such as conization or Loop Electrosurgical Excision Procedure (LEEP) prior to radiotherapy
Lab requirements
Blood counts
wbc ≥ 3,000/µl, anc ≥ 1,000/µl, platelets ≥ 100,000/µl, hemoglobin ≥ 9 g/dl
Kidney function
creatinine < 2.0 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify